依普利酮治疗高血压患者疗效如何？

Approved in the United States in 2002, it has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction, has fewer adverse reactions and is well tolerated. Eplerenone has a protective effect on the liver, heart disease, and kidneys without damaging the organs. Eplerenone can promote urination without losing potassium. 

How effective is eplerenone in treating patients with hypertension? 

Aldosterone is an important component present in the renin-angiotensin-aldosterone system (RAAS) and plays an important role in the regulation of the human cardiovascular system. According to the "American Journal of Hypertension", selective aldosterone receptor blockade eplerenone can effectively control mild to moderate hypertension and is well tolerated; studies have shown that eplerenone can cause sustained increases in plasma renin and serum aldosterone, and at the same time block the feedback regulatory effect of aldosterone, but the increase in plasma renin activity and the increase in systemic circulation aldosterone levels will not offset the blood pressure control effect of eplerenone. Eplerenone and spironolactone work on the same principle. Long-term use of spironolactone can cause endocrine disorders, while eplerenone has good tolerance and has the advantage of less side effects, avoiding the side effects of endocrine disorders.

  Eplerenone selectively acts on aldosterone receptors and is highly selective for mineralocorticoid receptors, but has less effect on androgen and progesterone receptors. Its affinity for mineralocorticoids is 15 to 20 times that of spironolactone, while its affinity for androgen and progesterone receptors is 500 times smaller than that of spironolactone, so sex hormone-related adverse reactions are less likely to occur.

Eplerenone treats patients with stage 1 and stage 2 hypertension with similar efficacy rates and reductions in systolic and diastolic blood pressure as enalapril. Eplerenone also has a good antihypertensive effect in patients with essential hypertension with low renin levels for whom angiotensin-converting enzyme inhibitors and angiotensin II receptor inhibitors are not effective. It also has a good antihypertensive effect on simple systolic hypertension, and has a good antihypertensive effect on diet-induced obesity-related hypertension. In addition, it can significantly reduce the ultrafiltration effect of glomeruli and reduce albuminuria in patients with hypertension. This renal protective effect is more obvious for patients with hypertension combined with diabetes.